Prescribing Medical Cannabis with Project Twenty21

---

Project Twenty21 is a registry aiming to monitor the health outcomes of 20,000 patients using cannabis based medicinal products (CBMPs), creating the largest body of evidence in Europe for the safety and efficacy of CBMPs.

Drug Science hope that the findings of Project Twenty21 will provide evidence for NHS funding where the benefits of treatment with medicinal cannabis is proven to outweigh the potential risks.

This real-world registry aims to target the following indications:

• Anxiety Disorder
• Chronic Pain
• Multiple Sclerosis (MS)
• Post-Traumatic Stress Disorder (PTSD)
• Substance Use Disorder (as a harm reduction strategy)
• Tourette’s Syndrome
• Adult Epilepsy

Drug Science is actively looking to expand the number of clinics offering Project Twenty21 and to train more specialist clinicians to be able to prescribe medical cannabis in the UK.

If you would like to find out more about prescribing medical cannabis, please email [email protected] and a member of the T21 team will be in touch.

Prescribing as part of Twenty21

Clinician specialising in one of the seven indications listed here who and would like to find out more about prescribing medical cannabis should email [email protected] for more information.